Evidence map›Paper›PMID 31200745›Full record

ArticleJournal of experimental & clinical cancer research : CR2019

USP13 functions as a tumor suppressor by blocking the NF-kB-mediated PTEN downregulation in human bladder cancer.

Xiaojun Man, Chiyuan Piao, Xuyong Lin, Chuize Kong, Xiaolu Cui, Yuanjun Jiang

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 113 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Ubiquitin Proteasome System Components, RAD23A and USP13, Modulate TDP-43 Solubility and Neuronal Toxicity.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2026
    Article
  6. Review
  7. Article
  8. NF-κB in inflammation and cancer.Cellular & molecular immunology · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Xiaojun ManDepartment of Urology, First hospital of China Medical University, No.155 Nanjing north Road, Shenyang, 110001, Liaoning, China.
Chiyuan PiaoDepartment of Urology, First hospital of China Medical University, No.155 Nanjing north Road, Shenyang, 110001, Liaoning, China.
Xuyong LinDepartment of Pathology, The First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, 110001, China.
Chuize KongDepartment of Urology, First hospital of China Medical University, No.155 Nanjing north Road, Shenyang, 110001, Liaoning, China.
Xiaolu CuiDepartment of Urology, First hospital of China Medical University, No.155 Nanjing north Road, Shenyang, 110001, Liaoning, China. cui_ruby@hotmail.com.
Yuanjun JiangDepartment of Urology, First hospital of China Medical University, No.155 Nanjing north Road, Shenyang, 110001, Liaoning, China. 13804064945@163.com.
First Hospital of China Medical University · CNChina Medical University · CN

Funding

National Natural Science Foundation of China No. 81702505
6 · The paper itself

Abstract

backgroundUSP13 has been reported to be involved in the tumorigenesis of human cancers, however, its functional role and regulatory mechanisms in bladder cancer (BC) remain unclear.

methodsq-RT-PCR was performed to examine the expression of miR-130b-3p, miR-301b-3p and USP13 in BC tissue samples. Western blot, q-RT-PCR, bioinformatic analysis and dual-luciferase reporter assay were conducted to identify the regulatory function of miR-130b-3p/301b-3p for USP13. Co-immunoprecipitation assay was performed to assess the interaction between USP13 and PTEN protein. Cell-counting-kit 8, colony formation assay and transwell assay were performed to value the proliferative, migrative and invasive capacities of BC cells in vitro. Mouse xenograft model of BC cells was established to verify the function of USP13 in vivo. Immunohistochemistry was performed to identify the protein expression of USP13, NF-kB p65 or PTEN in clinical/xenograft tumor tissues.

resultsOur present study reveals that USP13 functions as a tumor suppressor by interacting with PTEN protein and increasing its expression in bladder cancer. We found that loss of USP13 led to the downregulation of PTEN and promoted proliferative, invasive and migrative capacities of bladder cancer cells. Furthermore, we discovered that USP13 was a common target of miR-130b-3p and miR-301b-3p, and the miR-130b/301b cluster, which could be transcriptionally upregulated by NF-kB. Our data demonstrated that NF-kB activation decreased expression level of USP13 and PTEN, and promoted the tumorigenesis phenotypes of BC cells. In addition, reintroduction of USP13 partially rescued PTEN expression as well as the oncogenesis trend caused by NF-kB.

conclusionWe reported a potential regulatory loop that the NF-kB-induced miR-130b/301b overexpression decreased USP13 expression and subsequently resulted in the downregulation of PTEN protein and promoted tumorigenesis of bladder cancer. Moreover, NF-kB-mediated PTEN downregulation is very likely to facilitate the full activation of NF-kB.

Indexed as

Gene Expression Regulation, Neoplastic3' Untranslated RegionsAgedAged, 80 and overAnimalsApoptosisCarcinogenesisCell Line, TumorCell ProliferationDisease Models, AnimalEndopeptidasesHeterograftsHumansMiceMicroRNAsMiddle Aged3' Untranslated RegionsEndopeptidasesMicroRNAsNF-kappa BPTEN PhosphohydrolasePTEN protein, humanTumor Suppressor ProteinsUbiquitin-Specific ProteasesUSP13 protein, humanBladder cancerNF-kBPTENUSP13

Identifiers

PMID31200745
PMCPMC6570860
OpenAlexW2952306788

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.